Author name: R A

Roots Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 375+ page report, which […]

Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients

To order this detailed 640+ page report, please visit this link Key Inclusions A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage)

The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline

Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings The report features an in-depth analysis, highlighting the diverse capabilities of

Over the years, extensive R&D efforts have established the basis for a wide range of microbiome-based therapeutic and diagnostic products, which may cause a paradigm shift in the way healthcare is delivered in the foreseen future   Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings.  

To order this 550+ page report, please visit this link Key Inclusions A detailed review of the overall landscape of companies that are engaged in the manufacturing of cell-based therapies, including information on the type of cells manufactured (including immune cells (including T cells, dendritic cells, NK cells), stem cells (including adult stem cells, human

Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry

Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030, covering various important aspects of the industry and identifying key future growth opportunities. To order this 550+ page report, which features 160+ figures and 250+ tables, please visit this link Key Market Insights More than 100 industry players

Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030.” The report features an